Reproductive Organs Or Embryos Patents (Class 530/850)
-
Patent number: 7943334Abstract: The present invention provides an immunological detection method that can detect milk allergens, allergens of albumen, flour, buckwheat and peanut with high sensitivity in foods containing these allergens regardless they are denatured/native, and a detection kit to be used therefor. It is a method for detecting allergens by using 2 or more monoclonal antibodies recognizing native and denatured milk allergens, native and denatured albumen allergens, native and denatured flour allergens, native and denatured buckwheat allergens, and native and denatured peanut allergens, using asl casein which is the main protein of milk casein, ?-lactoglobulin which is the main protein of whey, ovalubumin and ovomucoid which are main proteins of albumen, gliadin which is the main protein of flour, protein with a molecular weight of 24 kDa and 76 kDa which are main proteins of buckwheat, and Ara h1 which is the main protein of peanut as an index.Type: GrantFiled: March 4, 2005Date of Patent: May 17, 2011Assignee: Prima Meat Packers, Ltd.Inventors: Masanobu Akimoto, Shigeki Katou, Makoto Namioka
-
Patent number: 7687610Abstract: The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the ?-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The invention is also directed to a human glycoprotein where at least one of the amino acids at position 58, 63, and 69 of the ?-subunit of the human thyroid stimulating hormone are basic amino acids. The invention is further directed to a modified human glycoprotein hormone having increased activity over a wild-type human glycoprotein hormone, where the modified human glycoprotein comprises a basic amino acid substituted at a position corresponding to the same amino acid position in a non-human glycoprotein hormone having an increased activity over the wild-type human glycoprotein hormone.Type: GrantFiled: April 21, 2006Date of Patent: March 30, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Mariusz W. Szkudlinski, Bruce D. Weintraub, Mathis Grossmann
-
Patent number: 7511123Abstract: Novels immuno-interactive fragments of the (alpha)C portion of a mammalian inhibin alpha subunit are disclosed, together with their variants and derivatives for producing antigen-binding molecules that are interactive with said (alpha)C portion, which are chemically well defined and which can be produced in commercially significant quantities. The antigen-binding molecules of the invention can be used for the detection of a mammalian inhibin and for the treatment and/or prevention of conditions associated with aberrant levels of a mammalian inhibin.Type: GrantFiled: April 18, 2002Date of Patent: March 31, 2009Assignee: Prince Henry's Institute of Medical ResearchInventors: David Mark Milne-Robertson, Peter Gordon Stanton, Nicholas Francis Cahir
-
Patent number: 7160676Abstract: This invention describes unique patterns of distribution of ganglioside GM1 in non-capacitated sperm and demonstrates that the pattern of distribution of GM1 undergoes changes that can be correlated with the process of capacitation and/or with acrosomal exocytosis. Accordingly, the present invention discloses a method for determining the ability of sperm to respond to capacitation and/or acrosomal exocytosis stimuli. The method comprises determination of distribution pattern for GM1. The method can be used for both diagnostic and predictive purposes when assessing male reproductive fitness, and can also be used to assess the effects on sperm of cryoprotective agents and protocols, and contraceptive agents.Type: GrantFiled: July 23, 2004Date of Patent: January 9, 2007Assignees: Cornell Research Foundation, Inc., Trustees of the University of PennsylvaniaInventors: Alexander J. Travis, Gregory S. Kopf
-
Patent number: 6767711Abstract: The present invention is directed to the use of antibodies or binding portions thereof or probes which recognize an antigen of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof. These antibodies or binding portions thereof or probes can be labeled and used for detection of such cells. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed is a hybridoma cell line which produces a monoclonal antibody recognizing antigens of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof.Type: GrantFiled: August 13, 2001Date of Patent: July 27, 2004Assignee: Cornell Research Foundation, Inc.Inventor: Neil H. Bander
-
Patent number: 6509316Abstract: The present invention relates to pharmaceutical compositions, methods and kits that provide for the early diagnosis and treatment of lung cancer. More particularly, the present invention relates to pharmaceutical compositions containing uteroglobin for preventing or inhibiting metastasis of lung tumor cells and methods of using the same to prevent or inhibit metastasis of lung tumor cells. The present invention also relates to methods and kits for early diagnosis of metastatic lung cancer by assaying for uteroglobin and comparing the results against control cells. The present invention also relates to methods and kits for detection of metastatic lung cancer by assaying for the presence of an aberrant form of uteroglobin.Type: GrantFiled: December 9, 1997Date of Patent: January 21, 2003Assignee: George Washington UniversityInventors: Steven R. Patierno, Michael J. Manyak
-
Patent number: 6469139Abstract: The present invention relates to modified human chorionic gonadotropin (&bgr;-hCG) proteins and their medical use as immunological contragestatives. The modification causes a reduction in the cross-reactivity of the modified &bgr;-hCG protein with luteinizing hormone (LH) as defined by the ability of both proteins to react with the same antibody.Type: GrantFiled: May 13, 1998Date of Patent: October 22, 2002Assignee: University College LondonInventors: Ivan Maurice Roitt, Peter John Delves, Torben Lund
-
Patent number: 6369195Abstract: Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.Type: GrantFiled: May 24, 2000Date of Patent: April 9, 2002Assignee: Urocor, Inc.Inventors: Gang An, Robert Veltri
-
Patent number: 6303123Abstract: Immunogenic compositions capable of generating an immune response in mammals against GnRH are disclosed. The immunogenic compositions are effective in methods of treating gonadotropin and gonadal steroid hormone dependent diseases and immunological contraception of mammals.Type: GrantFiled: June 7, 1995Date of Patent: October 16, 2001Assignee: Aphton CorporationInventors: Stephen Grimes, Robert Scibienski
-
Patent number: 6255281Abstract: Method for treatment of inflammatory and fibrotic conditions in vivo using pure rhUG is disclosed. Method for treating or preventing inflammatory or fibrotic conditions characterized by a deficiency of endogenous functional UG is also disclosed. Compositions containing pure rhUG, optionally also containing lung surfactant, and assay procedures for detection of UG-fibronectin complexes, are also provided.Type: GrantFiled: May 28, 1997Date of Patent: July 3, 2001Assignee: Claragen, Inc. and U.S. GovernmentInventors: Aprile L. Pilon, Anil B. Mukherjee, Zhongjian Zhang
-
Patent number: 6132720Abstract: Immunogenic compositions capable of generating an immune response in mammals against GnRH are disclosed. The immunogenic compositions are effective in methods of treating gonadotropin and gonadal steroid hormone dependent diseases and immunological contraception of mammals.Type: GrantFiled: November 17, 1997Date of Patent: October 17, 2000Assignee: Aphton Corp.Inventors: Stephen Grimes, Robert Scibienski
-
Patent number: 6103483Abstract: A purified polypeptide which provides for initial binding of sperm to oocyte investments and has an active amino acid sequence of SEQ ID NO:12 (Cys-Gln-Ser-Leu-Gln-Glu-Tyr-Leu-Ala-Glu-Gln-Asn-Gln-Arg-Gln-Leu-Glu-Ser-A sn-Lys-Ile-Pro-Glu-Val-Asp-Leu-Ala-Arg-Val-Val-Ala-Pro-Phe-Met-Ser-Asn-Ile- Pro-Leu-Leu-Leu-Tyr-Pro-Gln-Asp-Arg-Pro-Arg-Ser-Gln-Pro-Gln-Pro-Lys-Ala-Asn -Glu-Asp-Val-Cys); or SEQ ID NO:13 (Cys-Glu-Ser-Leu-Gln-Lys-His-Leu-Ala-Glu-Leu-Asn-His-Gln-Lys-Gln-Leu-Glu-S er-Asn-Lys-Ile-Pro-Glu-Leu-Asp-Met-Thr-Glu-Val-Val-Ala-Pro-Phe-Met-Ala-Asn- Ile-Pro-Leu-Leu-Leu-Tyr-Pro-Gln-Asp-Gly-Pro-Arg-Ser-Lys-Pro-Gln-Pro-Lys-Asp -Asn-Gly-Asp-Val-Cys); or the shorter but biologically active SEQ ID NO:1 and SEQ ID NO:9 (Tyr-Pro-Gln-Asp-Arg-X-Arg-Ser-Gln-Pro-Gln-Pro-Lys-Ala-Asn, where X is Thr or Pro).Type: GrantFiled: June 9, 1998Date of Patent: August 15, 2000Assignee: The Penn State Research FoundationInventors: Roy H. Hammerstedt, Palmer G. Cramer, Guy F. Barbato
-
Patent number: 6004586Abstract: A purified polypeptide which provides for initial binding of sperm to oocyte investments and has an active amino acid sequence of SEQ ID NO:12 (Cys-Gln-Ser-Leu-Gln-Glu-Tyr-Leu-Ala-Glu-Gln-Asn-Gln-Arg-Gln-Leu-Glu-Ser-A sn-Lys-Ile-Pro-Glu-Val-Asp-Leu-Ala-Arg-Val-Val-Ala-Pro-Phe-Met-Ser-Asn-Ile- Pro-Leu-Leu-Leu-Tyr-Pro-Gln-Asp-Arg-Pro-Arg-Ser-Gln-Pro-Gln-Pro-Lys-Ala-Asn -Glu-Asp-Val-Cys); or SEQ ID NO:13 (Cys-Glu-Ser-Leu-Gln-Lys-His-Leu-Ala-Glu-Leu-Asn-His-Gln-Lys-Gln-Leu-Glu-S er-Asn-Lys-Ile-Pro-Glu-Leu-Asp-Met-Thr-Glu-Val-Val-Ala-Pro-Phe-Met-Ala-Asn- Ile-Pro-Leu-Leu-Leu-Tyr-Pro-Gln-Asp-Gly-Pro-Arg-Ser-Lys-Pro-Gln-Pro-Lys-Asp -Asn-Gly-Asp-Val-Cys); or the shorter but biologically active SEQ ID NO:1 and SEQ ID NO:9 (Tyr-Pro-Gln-Asp-Arg-X-Arg-Ser-Gln-Pro-Gln-Pro-Lys-Ala-Asn, where X is Thr or Pro).Type: GrantFiled: February 20, 1998Date of Patent: December 21, 1999Assignee: The Penn State Research FoundationInventors: Roy H. Hammerstedt, Palmer G. Cramer, Guy F. Barbato
-
Patent number: 5972652Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.Type: GrantFiled: September 5, 1997Date of Patent: October 26, 1999Assignee: Genetics Institute, Inc.Inventors: Kenneth Jacobs, John M. McCoy, Lisa A. Racie, Edward R. LaVallie, David Merberg
-
Patent number: 5945302Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.Type: GrantFiled: January 13, 1997Date of Patent: August 31, 1999Assignee: Genetics Institute, Inc.Inventors: Kenneth Jacobs, John M. McCoy, Edward R. LaVallie, Lisa A. Racie, David Merberg
-
Patent number: 5932700Abstract: A novel cell growth-inhibiting protein is provided. The cell growth-inhibiting protein, obtainable from extract of human uterine endometrial carcinoma, has the amino acid sequence rich in hydrophobic residue at its N-terminal, has a molecular weight of about 68,000 dalton, and is considered to act as a paracrine growth-inhibiting factor in an organism.Type: GrantFiled: August 29, 1997Date of Patent: August 3, 1999Assignee: Suntory LimitedInventor: Atsushi Imai
-
Patent number: 5876730Abstract: Substantially pure heparin-binding growth factor polypeptides (HBGFs), nucleic acids encoding the HBGFs and antibodies which bind to the HBGFs of the invention are provided. The HBGF polypeptides are useful in methods for the induction of bone, cartilage and tissue formation, growth and development of the endometrium and in the acceleration of wound healing. HBGF is related to Connective Tissue Growth Factor (CTGF).Type: GrantFiled: August 7, 1997Date of Patent: March 2, 1999Assignee: Childrens Hospital Research FoundationInventors: David R. Brigstock, Paul A. Harding
-
Patent number: 5864011Abstract: A method of determining the prognosis of a solid tumor is provided, in which a sample from a patient bearing a tumor is assayed for the presence of a protein which is immunologically cross-reactive with the hpr gene product, but not with haptoglobin 1 or haptoglobin 2. Also provided is a method for preparing antibodies specific for this diagnostic marker which correlates with early relapse and metastasis of breast and other cancers. The marker can be detected using immunological methods employing antibodies specific for Hpr protein and not cross-reactive with haptoglobins 1 or 2.Type: GrantFiled: June 5, 1995Date of Patent: January 26, 1999Assignee: The Johns Hopkins UniversityInventors: Francis P. Kuhajda, Gary R. Pasternack
-
Patent number: 5849713Abstract: The invention relates to chemotactic factors for human spermatozoa that are purifiable from human follicular fluid. The factors are of peptidic and hydrophilic nature and have, one, a molecular size of about 13 kDa and, the other, an apparent molecular size smaller than 1.3 kDa, as determined by high pressure gel filtration. They are for use in procedures related to human fertilization, such as in various types of assisted fertilization, particularly artificial insemination, in vitro fertilization, micromanipulation and direct microinjection of sperm into oocytes.Type: GrantFiled: January 5, 1996Date of Patent: December 15, 1998Assignee: Yeda Research and Development Co. Ltd.Inventor: Michael Eisenbach
-
Patent number: 5831035Abstract: An antibody to the purified and isolated glycoprotein and functional analogs thereof characterized by being progesterone induced and estradiol inhibited secretory glycoprotein specifically from stromal cells of endometrial origin. The protein has the molecular weight of 70,000 daltons as determined by two-dimensional SDS-PAGE polyacrylamide gel electrophoresis and has an isoelectric point of 5.7.Type: GrantFiled: October 25, 1994Date of Patent: November 3, 1998Assignee: Curators of the University of MissouriInventor: Kathy L. Timms
-
Patent number: 5820863Abstract: The invention relates to antigenic preparations useful for inducing the production of antibodies in an individual which will bind to epitopes on zona pellucida. Also disclosed are immunogenic compositions and methods for immunizing an individual to enable the production of antibodies to zona pellucida antigens. Also disclosed are the use of these recombinant molecules and monoclonal antibodies thereto for immunocontraception or sterilization.Type: GrantFiled: February 28, 1995Date of Patent: October 13, 1998Assignee: Zonagen, Inc.Inventor: Bonita Sue Dunbar
-
Patent number: 5708157Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.Type: GrantFiled: July 26, 1996Date of Patent: January 13, 1998Assignee: Genetics Institute, Inc.Inventors: Kenneth Jacobs, John M. McCoy, Edward R. LaVallie, Lisa A. Racie, David Merberg, Maurice Treacy, Cheryl Evans, Vikki Spaulding
-
Patent number: 5691455Abstract: The present invention relates to gonadotropins consisting of an .alpha. and .beta. subunit, said gonadotropins comprising non-native disulfide bridges, preferably non-native intersubunit disulfide bridges. The gonadotropins according to the invention have improved stability. The present invention furthermore provides for pharmaceutical compositions comprising said gonadotropins.Type: GrantFiled: November 9, 1995Date of Patent: November 25, 1997Assignee: Akzo Nobel N.V.Inventors: Pieter Diederik Jan Grootenhuis, Judith Christina Heikoop
-
Patent number: 5688506Abstract: Immunogenic compositions capable of generating an immune response in mammals against GnRH are disclosed. The immunogenic compositions are effective in methods of treating gonadotropin and gonadal steroid hormone dependent diseases and immunological contraception of mammals.Type: GrantFiled: January 27, 1994Date of Patent: November 18, 1997Assignee: Aphton Corp.Inventors: Stephen Grimes, Robert Scibienski
-
Patent number: 5559097Abstract: Methods and compositions are provided for maintaining pregnancy and preventing rejection of transplanted tissue. A polypeptide characterized as capable of isolation from conceptus tissue and capable of inhibiting mitogen induced lymphocyte blastogenesis is employed which is introduced into the uterus or systemically.Type: GrantFiled: January 12, 1990Date of Patent: September 24, 1996Assignee: Idaho Research Foundation, Inc.Inventor: R. Garth Sasser
-
Patent number: 5554595Abstract: Based on the discovery that normal pregnant mice have a striking reduction in committed precursors of B lymphocytes, which could be documented in mice as early as day 6 of gestation, when IL-7 responding colony forming cells were reduced as much as two-thirds of normal levels, it has been determined that estrogen and other hormones elevated in pregnancy induce a specific modulation of lymphocyte formation during pregnancy and lactation. It is therefore possible to immunomodulate in a specific manner an animal by administration of hormones elevated during pregnancy, such as estrogen and estrogen-like compounds, or antagonists of estrogen. This has potential in the treatment of a number of disorders, especially those found in very high percentages of women as compared with men, such as many of the autoimmune disorders, as well as in immune tolerance during pregnancy, cyclic neutropenia, and osteoporosis.Type: GrantFiled: October 11, 1994Date of Patent: September 10, 1996Assignee: Oklahoma Medical Research FoundationInventors: Paul W. Kincade, Kay L. Medina
-
Patent number: 5549904Abstract: A formulated biological adhesive composition utilizes tissue transglutaminase in a pharmaceutically acceptable aqueous carrier. The tissue transglutaminase is used in an effective catalytic amount to promote adhesion between tissue surfaces upon treatment thereof by catalyzing the reaction between glutaminyl residues and amine donors of the tissue and/or the enzyme. The carrier contains a divalent metal ion such as calcium to promote said reaction.Type: GrantFiled: June 3, 1993Date of Patent: August 27, 1996Assignee: Orthogene, Inc.Inventors: Kay Juergensen, Daniel Aeschlimann, Ernst B. Hunziker
-
Patent number: 5516754Abstract: By the combined use of an agent which selectively dissolves tumor cells and which contains a protein fraction which has oxygen-liberating action and which is derived from the photosynthetic system of plants, together with a further agent which inhibits the proteases of the cancer cells and which has been obtained by means of extraction of embryonic tissue or maternal uterus tissue from placentals, it is possible to selectively dissolve the tumor by means of this agent without damaging the healthy organism. When used on its own, the abovementioned plant-derived agent shows an activity in the treatment of inflammatory processes and is also suitable for the aftertreatment of scars, keloids and damage caused by ionizing rays.Type: GrantFiled: January 24, 1994Date of Patent: May 14, 1996Inventor: Adolf Lofflmann
-
Patent number: 5494899Abstract: It has been determined that estrogen and other hormones elevated in pregnancy induce a specific modulation of lymphocyte precursor cell production. The immune system of an animal or bone marrow cells in culture can therefore be modulated in a specific manner by administration of hormones elevated during pregnancy, such as estrogen and estrogen-like compounds or compounds that interfere with the synthesis or activity of these hormones, to increase or decrease production of B lymphocyte precursor cells.Type: GrantFiled: April 7, 1994Date of Patent: February 27, 1996Assignee: Oklahoma Medical Research FoundationInventors: Paul W. Kincade, Kay Medina
-
Patent number: 5470826Abstract: Polypeptides exhibiting an inhibitory action over follitropin are disclosed. These polypeptides are designated follitropin suppressing proteins, or "FSP's," and range in size from 30 to 60 kD as determined by SDS-PAGE. Uses for FSP's, including regulation of fertility and as immunogens, are disclosed.Type: GrantFiled: November 3, 1993Date of Patent: November 28, 1995Assignees: Biotechnology Australia Pty Ltd., Monash University, Monash Medical Centre, St. Vincents Institute of Medical ResearchInventors: David M. De Kretser, Henry G. Burger, Milton T. W. Hearn, David M. Milne-Robertson, Richard E. H. Wettenhall, Robert I. McLachlan, Fiona De Vos
-
Patent number: 5449757Abstract: Mammalian adipogenic factors, including purified proteins or glycoproteins, capable of inducing the adipose differentiation of adipogenic cells are disclosed, as are antibodies to such proteins, DNA encoding the proteins and host cells expressing the proteins. A method for determining the susceptibility of a subject to obesity by measuring the levels of one or more adipogenic factors in a biological fluid or tissue extract is also disclosed, as is a method for evaluating an anti-obesity drug which comprises contacting the drug with cells capable of producing one or more adipogenic factors and measuring the amount of the factors produced.Type: GrantFiled: March 22, 1994Date of Patent: September 12, 1995Assignee: W. Alton Jones Cell Science CenterInventor: Ginette Serrero
-
Patent number: 5270057Abstract: Disclosed are lyophilized gonadotropin containing preparations containing a dicarboxylic acid salt stabilizer. The particular proteins (e.g. LH, TSH, FSH, or HCG) are in admixture with, and at least partially capable of stabilization by, the particular stabilizer in lyophilized form. The preparations contain a sufficient amount of dicarboxylic acid salt to stabilize the protein in freeze-dried form for a desired time at a desired temperature. Typical dicarboxylic acid salts disclosed are the salts of citric, tartaric, and aspartic acids. The preparations preferably include a non-reducing disaccharide to increase the collapse temperature of the solution to be lyophilized. Methods of making the preparations in lyophilized form and the resulting injectable preparations are also disclosed.Type: GrantFiled: July 13, 1992Date of Patent: December 14, 1993Assignee: Akzo N.V.Inventors: Andreas L. J. de Meere, Marinus A. De Ruiter
-
Patent number: 5211952Abstract: Contraceptive devices which are effective for extended periods of time are described, in the form of means for releasing an effective amount of a gonadotropin hormone releasing hormone composition and means for releasing an effective amount of an estrogenic hormone over a first period of time, and means for releasing an effective amount of a progestogen for a second period of time, the second period of time being substantially shorter than and running simultaneously with a portion of the first period of time. The gonadotropin hormone releasing hormone composition is selected from gonadotropin hormone releasing hormone, gonadotropin hormone releasing hormone analogues, gonadotropin hormone releasing hormone agonists, gonadotropin hormone releasing hormone antagonists and mixtures thereof. Contraceptive methods employing the devices are also described.Type: GrantFiled: April 12, 1991Date of Patent: May 18, 1993Assignee: University of Southern CaliforniaInventors: Darcy V. Spicer, Malcolm C. Pike
-
Patent number: 5140100Abstract: A substance having an inhibitory effect on the production of human choriogonadotropin (hCG) is described, which comprises a protein isolated from human decidual cells with a molecular weight of about 7,000 to about 10,000 daltons, and useful for use in inhibiting production of hCG in vivo or in vitro or may be measured as an indication of a cause of hCG inhibition.Type: GrantFiled: December 28, 1990Date of Patent: August 18, 1992Assignee: Cedars-Sinai Medical CenterInventors: Glenn A. Braunstein, Song-Guang Ren
-
Patent number: 5102807Abstract: A protein which satisfies all the biological criteria which are characteristic of inhibin has been isolated from a gonadal source. The purification and characterization of inhibin and the use of the purified material to raise antibodies, the use of inhibin and said antisera in a quantative radioimmunoassay, and applications in vitro and in vivo of inhibin and antibody to inhibin, are described.There is provided a purified protein, inhibin, characterised in thata. the apparent molecular weight as determined by SDS-PAGE is 56,000.+-.1,000b. the isoelectric point is in the range 6.9-7.3c. the protein can bind specifically to Concanavalin A-Sepharosed the protein consists of two sub-units, characterized in thati. their apparent molecular weights as determined by SDS-PAGE are 44,000.+-.3,000 and 14,000.+-.2,000 respectively.ii. the isoelectric point of the 44,000 molecular weight sub-unit is in the range 6.0-7.0iii. the N-terminal amino acid sequences of the two sub-units are as described hereine.Type: GrantFiled: April 11, 1989Date of Patent: April 7, 1992Assignees: Biotechnology Australia Pty Ltd., Monash University, St. Vincent's Institute of Medical Research, Monash Medical CentreInventors: Henry G. Burger, David M. de Kretser, John K. Findlay, Francis J. Morgan, Milton T. W. Hearn, David Milne-Robertson, Robert G. Forage, Richard E. H. Weitenhall
-
Patent number: 4996297Abstract: The invention relates to antigenic preparations useful for inducing the production of antibodies in an individual which will bind to epitopes on zona pellucida. Also disclosed are immunogenic compositions and methods for immunizing an individual to enable the production of antibodies to zona pellucida antigens. Also disclosed are the use of these recombinant molecules and monoclonal antibodies thereto for immunocontraception or sterilization.Type: GrantFiled: October 7, 1987Date of Patent: February 26, 1991Assignee: Zonagen, Inc.Inventor: Bonita S. Dunbar
-
Patent number: 4973578Abstract: Synthetic peptides corresponding to .alpha.-subunit of human glycoprotein hormone amino acid regions .alpha.31-45, .alpha.21-35, .alpha.26-46 and .alpha.81-92; were found to inhibit binding of 125.sub.I-bTSH to human thyroid. Peptides corresponding to regions .alpha.26-46 and .alpha.31-45 were also found to potently inhibit the stimulation of adenylate cyclase activity by bTSH in a TSH bioassay using FRTL-5 cells and block the action of thyroid stimulating immunoglobulin.Type: GrantFiled: March 17, 1988Date of Patent: November 27, 1990Assignee: Mayo Foundation for Medical Education and ResearchInventors: Robert J. Ryan, Daniel J. McCormick, John C. Morris, M. Cristine Charlesworth
-
Patent number: 4919889Abstract: Sensitive proteins in human biological secretion samples are preserved by dispersing them in an aqueous solution containing from 0.05 to 0.5M of a buffer which is effective to maintain the solution pH within the range of from 6.5 to 8.0; from 0.1 to 10 wt. % of a non-immune animal protein selected from the group consisting of albumin, ovalbumin, casein, glycoprotein and mixtures thereof; from 40 to 2000 kallikrein units/mL of an enzyme inhibitor of trypsin, chymotrypsin, kallikrein or plasmin; and from 0.01 to 0.1 wt. % of a bacteriostatic agent. The solution preferably also contains from 5 .mu.M to 1 mM of a protease inhibitor; and from 1 to 10 mM of a chelating agent. Optimally, the enzyme inhibitor is aprotinin, the protease inhibitor is phenylmethylsulfonylfluoride, the non-immune animal protein is bovine serum albumin, and the protease inhibitor is phenylmethylsulfonylfluoride. 0.0 to 0.15 mM of a water-soluble non-interfering salt, such as NaCl, may be desired.Type: GrantFiled: September 15, 1988Date of Patent: April 24, 1990Assignee: Aspen Diagnostics CorporationInventors: Lynn A. Jones, Lloyd H. Smith, Nelson N. H. Teng
-
Patent number: 4882270Abstract: There are provided monoclonal antibodies which react with human oncofetal ferritin and which do not react with human spleen ferritin or with liver ferritin; there are also provided monoclonal antibodies which react both with human placenta oncofetal ferritin and with human adult spleen ferritin. There is provided a process for producing clones producing such antibodies and such clones, and an assay for the detection of human breast cancer based on the determination of oncofetal ferritin, which assay is based on such monoclonal antibodies.Type: GrantFiled: January 22, 1988Date of Patent: November 21, 1989Inventor: Chaya Moroz
-
Patent number: 4882421Abstract: Rana pipiens eggs are subjected to fertilization and the embryos are grown to a predetermined stage of development. The embryos and unfertilized eggs are then subjected to mechanical processing in the presence of a weakly acidic buffer to produce an extract. The extract is subjected to ion-exchange chromatography and size-exclusion chromatography.The resulting pharmaceutical has activity against certain cancer cells. A partial amino acid sequence of the pharmaceutical is disclosed.Type: GrantFiled: April 6, 1988Date of Patent: November 21, 1989Assignee: Alfacell CorporationInventors: Kuslima Shogen, Stanislaw M. Mikulski, Wojciech J. Ardelt
-
Patent number: 4755460Abstract: A bovine pregnancy antigen, determined to be a glycoprotein, has been isolated and purified. If is diagnostic for the presence of pregnancy in cattle when detected by the use of antibodies to the antigen.Type: GrantFiled: July 6, 1984Date of Patent: July 5, 1988Assignee: The Regents of the Univ. of MinnesotaInventors: Eileen F. Bostwick, Alan G. Hunter
-
Patent number: RE33405Abstract: A prostate antigen distinct from prostatic acid phosphatase has been detected in normal, benign hypertrophic and malignant prostatic tissues, but not in other human tissues. The prostate antigen was purified to homogeneity from prostatic tissues by ammonium sulfate precipitation, DEAE-BioGel A anion exchange chromatography, molecular sievings on Sephadex G-100 and Sephadex G-75,This invention was supported in part by Grants No. CA-15126 and CA-15437 from the National Cancer Institute, U.S. Public Health Service.Type: GrantFiled: October 4, 1988Date of Patent: October 23, 1990Assignee: Research Corporation Technologies, Inc.Inventors: Tsann M. Chu, Ming C. Wang, Lawrence Papsidero